Measurement of (18)F-FDG PET tumor heterogeneity improves early assessment of response to bevacizumab compared with the standard size and uptake metrics in a colorectal cancer model

PURPOSE: Treatment of metastatic colorectal cancer frequently includes antiangiogenic agents such as bevacizumab. Size measurements are inadequate to assess treatment response to these agents, and newer response assessment criteria are needed. We aimed to evaluate (18)F-FDG PET-derived texture param...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Nucl Med Commun
Prif Awduron: Bashir, Usman, Weeks, Amanda, Goda, Jayant S., Siddique, Muhammad, Goh, Vicky, Cook, Gary J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Lippincott Williams & Wilkins 2019
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553522/
https://ncbi.nlm.nih.gov/pubmed/30893213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MNM.0000000000000992
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg